Review ArticleClinical Review

Efficacy, Safety, and Tolerability of Low-Dose Hormone Therapy in Managing Menopausal Symptoms

Robert D. Langer
The Journal of the American Board of Family Medicine September 2009, 22 (5) 563-573; DOI: https://doi.org/10.3122/jabfm.2009.05.080134

References

  1. ↵
    American College of Obstetricians and Gynecologists, Women's Health Care Physicians. ACOG practice bulletin. Clinical management guidelines for obstetrician-gynecologists. Number 50, January 2003. Obstet Gynecol 2004; 103: 203–16.
    OpenUrlPubMed
  2. ↵
    Rossouw JE, Anderson GL, Prentice RL, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA 2002; 288: 321–33.
    OpenUrlCrossRefPubMedWeb of Science
  3. ↵
    Anderson GL, Limacher M, Assaf AR, et al. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial. JAMA 2004; 291: 1701–12.
    OpenUrlCrossRefPubMedWeb of Science
  4. ↵
    Rossouw JE, Prentice RL, Manson JE, et al. Postmenopausal hormone therapy and risk of cardiovascular disease by age and years since menopause. JAMA 2007; 297: 1465–77.
    OpenUrlCrossRefPubMedWeb of Science
  5. ↵
    Wassertheil-Smoller S, Hendrix S, Limacher M, et al. Effect of estrogen plus progestin on stroke in postmenopausal women: The Women's Health Initiative: a randomized trial. JAMA 2003; 289: 2673–84.
    OpenUrlCrossRefPubMedWeb of Science
  6. Cushman M, Kuller LH, Prentice R, et al. Estrogen plus progestin and risk of venous thrombosis. JAMA 2004; 292: 1573–80.
    OpenUrlCrossRefPubMedWeb of Science
  7. ↵
    Chlebowski RT, Hendrix SL, Langer RD, et al. Influence of estrogen plus progestin on breast cancer and mammography in healthy postmenopausal women: the Women's Health Initiative randomized trial. JAMA 2003; 289: 3243–53.
    OpenUrlCrossRefPubMedWeb of Science
  8. Anderson GL, Chlebowski RT, Rossouw JE, et al. Prior hormone therapy and breast cancer risk in the Women's Health Initiative randomized trial of estrogen plus progestin. Maturitas 2006; 55: 103–15.
    OpenUrlCrossRefPubMedWeb of Science
  9. Chlebowski RT, Wactawski-Wende J, Ritenbaugh C, et al. Estrogen plus progestin and colorectal cancer in postmenopausal women. N Engl J Med 2004; 350: 991–1004.
    OpenUrlCrossRefPubMedWeb of Science
  10. Cauley JA, Robbins J, Chen Z, et al. Effects of estrogen plus progestin on risk of fracture and bone mineral density: the Women's Health Initiative randomized trial. JAMA 2003; 290: 1729–38.
    OpenUrlCrossRefPubMedWeb of Science
  11. ↵
    Curb JD, Prentice RL, Bray PF, et al. Venous thrombosis and conjugated equine estrogen in women without a uterus. Arch Intern Med 2006; 166: 772–80.
    OpenUrlCrossRefPubMedWeb of Science
  12. Ritenbaugh C, Stanford JL, Wu L, et al. Conjugated equine estrogens and colorectal cancer incidence and survival: the Women's Health Initiative randomized clinical trial. Cancer Epidemiol Biomarkers Prev 2008; 17: 2609–18.
    OpenUrlAbstract/FREE Full Text
  13. Stefanick ML, Anderson GL, Margolis KL, et al. Effects of conjugated equine estrogens on breast cancer and mammography screening in postmenopausal women with hysterectomy. JAMA 2006; 295: 1647–57.
    OpenUrlCrossRefPubMedWeb of Science
  14. ↵
    Archer DF. Lower doses of oral estrogen and progestogens as treatment for postmenopausal women. Semin Reprod Med 2005; 23: 188–95.
    OpenUrlPubMed
  15. ↵
    Ettinger B. Rationale for use of lower estrogen doses for postmenopausal hormone therapy. Maturitas 2007; 57: 81–4.
    OpenUrlPubMed
  16. ↵
    Grodstein F, Manson JE, Stampfer MJ. Hormone therapy and coronary heart disease: the role of time since menopause and age at hormone initiation. J Womens Health 2006; 15: 35–44.
    OpenUrlCrossRefWeb of Science
  17. ↵
    Skouby SO, Al-Azzawi F, Barlow D, et al. Climacteric medicine: European Menopause and Andropause Society (EMAS) 2004/2005 position statements on peri- and postmenopausal hormone replacement therapy. Maturitas 2005; 51: 8–14.
    OpenUrlCrossRefPubMedWeb of Science
  18. ↵
    North American Menopause Society. Estrogen and progestogen use in peri- and postmenopausal women: March 2007 position statement of The North American Menopause Society. Menopause 2007; 14: 168–82.
    OpenUrlCrossRefPubMedWeb of Science
  19. ↵
    Pickar JH, Yeh I-T, Wheeler JE, Cunnane MF, Speroff L. Endometrial effects of lower doses of conjugated equine estrogens and medroxyprogesterone acetate. Fertil Steril 2001; 76: 25–31.
    OpenUrlCrossRefPubMedWeb of Science
  20. ↵
    Pickar JH, Yeh I-T, Wheeler JE, Cunnane MF, Speroff L. Endometrial effects of lower doses of conjugated equine estrogens and medroxyprogesterone acetate: two year substudy results. Fertil Steril 2003; 80: 1234–40.
    OpenUrlCrossRefPubMed
  21. ↵
    Warren MP. Historical perspectives in postmenopausal hormone therapy: defining the right dose and duration. Mayo Clin Proc 2007; 82: 219–26.
    OpenUrlCrossRefPubMed
  22. ↵
    Bachmann GA, Schaefers M, Uddin A, Utian WH. Lowest effective transdermal 17β-estradiol dose for relief of hot flushes in postmenopausal women: a randomized controlled trial. Obstet Gynecol 2007; 110: 771–9.
    OpenUrlCrossRefPubMed
  23. Diem S, Grady D, Quan J, et al. Effects of ultralow-dose transdermal estradiol on postmenopausal symptoms in women aged 60 to 80 years. Menopause 2006; 13: 130–8.
    OpenUrlPubMed
  24. ↵
    Rebar RW, Trabal J, Mortola J. Low-dose esterified estrogens (0.3 mg/day): long-term and short-term effects on menopausal symptoms and quality of life in postmenopausal women. Climacteric 2000; 3: 176–82.
    OpenUrlPubMed
  25. ↵
    Utian WH, Shoupe D, Bachmann G, Pinkerton JV, Pickar JH. Relief of vasomotor symptoms and vaginal atrophy with lower doses of conjugated equine estrogens and medroxyprogesterone acetate. Fertil Steril 2001; 75: 1065–79.
    OpenUrlCrossRefPubMedWeb of Science
  26. Utian WH, Burry KA, Archer DF, et al. Efficacy and safety of low, standard, and high dosages of an estradiol transdermal system (Esclim) compared with placebo on vasomotor symptoms in highly symptomatic menopausal patients. Am J Obstet Gynecol 1999; 181: 71–9.
    OpenUrlCrossRefPubMedWeb of Science
  27. Speroff L, Whitcomb RW, Kempfert NJ, Boyd RA, Paulissen JB, Rowan JP. Efficacy and local tolerance of a low-dose, 7-day matrix estradiol transdermal system in the treatment of menopausal vasomotor symptoms. Obstet Gynecol 1996; 88(4 Pt 1): 587–92.
    OpenUrlCrossRefPubMedWeb of Science
  28. ↵
    Panay N, Ylikorkala O, Archer DF, Gut R, Lang E. Ultra-low-dose estradiol and norethisterone acetate: effective menopausal symptom relief. Climacteric 2007; 10: 120–31.
    OpenUrlCrossRefPubMedWeb of Science
  29. ↵
    Notelovitz M, Mattox JH. Suppression of vasomotor and vulvovaginal symptoms with continuous oral 17β-estradiol. Menopause 2000; 7: 310–7.
    OpenUrlPubMedWeb of Science
  30. Speroff L, Symons J, Kempfert N, Rowan J. The effect of varying low-dose combinations of norethindrone acetate and ethinyl estradiol (Femhrt) on the frequency and intensity of vasomotor symptoms. Menopause 2000; 7: 383–90.
    OpenUrlCrossRefPubMedWeb of Science
  31. Gadomska H, Barcz E, Cyganek A, Leocmach Y, Chadha-Boreham H, Marianowski L. Efficacy and tolerability of low-dose transdermal estrogen (Oesclim) in the treatment of menopausal symptoms. Curr Med Res Opin 2002; 18: 97–102.
    OpenUrlPubMed
  32. ↵
    Johnson SR, Ettinger B, Macer JL, Ensrud KE, Quan J, Grady D. Uterine and vaginal effects of unopposed ultralow-dose transdermal estradiol. Obstetricians Gynecol 2005; 105: 779–87.
    OpenUrl
  33. ↵
    Wyeth Pharmaceuticals. Premarin (conjugated estrogens tablets, USP) product information. Philadelphia, PA: Wyeth Pharmaceuticals, 2006.
  34. Pharmacia & Upjohn Company Estring (estradiol vaginal ring 2 mg) product information. New York, NY: Pharmacia & Upjohn Company, 2007.
  35. ↵
    Novo Nordisk Inc. Vagifem (estradiol vaginal tablets 25 μg) product information. Princeton, NJ: Novo Nordisk Inc., 2003.
  36. ↵
    North American Menopause Society. The role of local vaginal estrogen for treatment of vaginal atrophy in postmenopausal women: 2007 position statement of The North American Menopause Society. Menopause 2007; 14(3 Pt 1): 355–69.
    OpenUrlCrossRefPubMed
  37. ↵
    Bachmann G, Lobo RA, Gut R, Nachtigall L, Notelovitz M. Efficacy of low-dose estradiol vaginal tablets in the treatment of atrophic vaginitis: a randomized controlled trial. Obstet Gynecol 2008; 111: 67–76.
    OpenUrlCrossRefPubMed
  38. ↵
    Manonai J, Chittacharoen A, Theppisai U. Transvaginal color Doppler sonographic assessment of uterus and ovaries in postmenopausal women: the effect of local estrogen treatment. Eur J Obstet Gynecol Reprod Biol 2006; 127: 222–6.
    OpenUrlPubMed
  39. ↵
    Prestwood KM, Kenny AM, Unson C, Kulldorff M. The effect of low dose micronized 17β-estradiol on bone turnover, sex hormone levels, and side effects in older women: a randomized, double blind, placebo-controlled study. J Clin Endocrinol Metab 2000; 85: 4462–9.
    OpenUrlCrossRefPubMedWeb of Science
  40. ↵
    Lindsay R, Gallagher JC, Kleerekoper M, Pickar JH. Effect of lower doses of conjugated equine estrogens with and without medroxyprogesterone acetate on bone in early postmenopausal women. JAMA 2002; 287: 2668–76.
    OpenUrlCrossRefPubMedWeb of Science
  41. ↵
    Speroff L, Rowan J, Symons J, Genant H, Wilborn W. The comparative effect on bone density, endometrium, and lipids of continuous hormones as replacement therapy (CHART Study): a randomized controlled trial. JAMA 1996; 276: 1397–403.
    OpenUrlCrossRefPubMedWeb of Science
  42. ↵
    Effects of estrogen or estrogen/progestin regimens on heart disease risk factors in postmenopausal women: Postmenopausal Estrogen/Progestin Interventions (PEPI) Trial. The Writing Group for the PEPI Trial. JAMA 1995; 273: 199–208.
    OpenUrlCrossRefPubMedWeb of Science
  43. ↵
    Barnabei VM, Cochrane BB, Aragaki AK, et al. Menopausal symptoms and treatment-related effects of estrogen and progestin in the Women's Health Initiative. Obstet Gynecol 2005; 105: 1063–73.
    OpenUrlPubMedWeb of Science
  44. ↵
    Greendale GA, Reboussin BA, Sie A, et al. Effects of estrogen and estrogen-progestin on mammographic parenchymal density. Ann Intern Med 1999; 130(4 Pt 1): 262–9.
    OpenUrlPubMedWeb of Science
  45. ↵
    Cline JM, Soderqvist G, von Schoultz E, Skoog L, von Schoultz B. Effects of hormone replacement therapy on the mammary gland of surgically postmenopausal cynomolgus macaques. Am J Obstet Gynecol 1996; 174: 93–100.
    OpenUrlCrossRefPubMedWeb of Science
  46. ↵
    Symons J, Kempfert N, Speroff L. Vaginal bleeding in postmenopausal women taking low-dose norethindrone acetate and ethinyl estradiol combinations. Obstet Gynecol 2000; 96: 366–72.
    OpenUrlCrossRefPubMedWeb of Science
  47. ↵
    Archer DF, Dorin M, Lewis V, Schneider DL, Pickar JH. Effects of lower doses of conjugated equine estrogens and medroxyprogesterone acetate on endometrial bleeding. Fertil Steril 2001; 75: 1080–7.
    OpenUrlCrossRefPubMedWeb of Science
  48. ↵
    Johannes CB, Crawford SL, Posner JG, McKinlay SM. Longitudinal patterns and correlates of hormone replacement therapy use in middle-aged women. Am J Epidemiol 1994; 140: 439–52.
    OpenUrlAbstract/FREE Full Text
  49. ↵
    Hill DA, Weiss NS, LaCroix AZ. Adherence to postmenopausal hormone therapy during the year after the initial prescription: a population-based study. Am J Obstet Gynecol 2000; 182: 270–6.
    OpenUrlCrossRefPubMedWeb of Science
  50. ↵
    Porch JV, Lee IM, Cook NR, Rexrode KM, Burin JE. Estrogen-progestin replacement therapy and breast cancer risk: the Women's Health Study (United States). Cancer Causes Control 2002; 13: 847–54.
    OpenUrlCrossRefPubMedWeb of Science
  51. ↵
    Breast cancer and hormone replacement therapy: collaborative reanalysis of data from 51 epidemiological studies of 52,705 women with breast cancer and 108,411 women without breast cancer. Collaborative Group on Hormonal Factors in Breast Cancer. Lancet 1997; 350: 1047–59.
    OpenUrlCrossRefPubMedWeb of Science
  52. ↵
    McCormack VA, dos Santos Silva I. Breast density and parenchymal patterns as markers of breast cancer risk: a meta-analysis. Cancer Epidemiol Biomarkers Prev 2006; 15: 1159–69.
    OpenUrlAbstract/FREE Full Text
  53. ↵
    Boyd NF, Martin LJ, Li Q, et al. Mammographic density as a surrogate marker for the effects of hormone therapy on risk of breast cancer. Cancer Epidemiol Biomarkers Prev 2006; 15: 961–6.
    OpenUrlAbstract/FREE Full Text
  54. ↵
    Yaffe M, Hendrix S, Pike M, Santen R, Eden J, Genazzani A. Is mammographic density, as currently measured, a robust surrogate marker for breast cancer? Gynecol Endocrinol 2005; 21(Suppl 1): 17–21.
    OpenUrlPubMed
  55. ↵
    Beral V, Million Women Study Collaborators. Breast cancer and hormone-replacement therapy in the Million Women Study. Lancet 2003; 362: 419–27.
    OpenUrlCrossRefPubMedWeb of Science
  56. ↵
    Foidart JM, Desreux J, Pintiaux A, Gompel A. Hormone therapy and breast cancer risk. Climacteric 2007; 10(Suppl 2): 54–61.
    OpenUrlPubMed
  57. ↵
    Boyd NF, Rommens JM, Vogt K, et al. Mammographic breast density as an intermediate phenotype for breast cancer. Lancet Oncol 2005; 6: 798–808.
    OpenUrlCrossRefPubMedWeb of Science
  58. ↵
    Lundström E, Bygdeson M, Svane G, Azavedo E, Von Schoultz B. Neutral effect of ultra-low-dose continuous combined estradiol and norethisterone acetate on mammographic breast density. Climacteric 2007; 10: 249–56.
    OpenUrlCrossRefPubMed
  59. ↵
    Jick H, Derby LE, Myers MW, Vasilakis C, Newton KM. Risk of hospital admission for idiopathic venous thromboembolism among users of postmenopausal oestrogens. Lancet 1996; 348: 981–3.
    OpenUrlCrossRefPubMedWeb of Science
  60. ↵
    Canonico M, Oger E, Plu-Bureau, et al. Hormone therapy and venous thromboembolism among postmenopausal women: impact of the route of estrogen administration and progestogens: the ESTHER study. Circulation 2007; 115: 840–5.
    OpenUrlAbstract/FREE Full Text
  61. ↵
    Grodstein F, Manson JE, Colditz GA, Willett WC, Speizer FE, Stampfer MJ. A prospective, observational study of postmenopausal hormone therapy and primary prevention of cardiovascular disease. Ann Intern Med 2000; 133: 933–41.
    OpenUrlCrossRefPubMedWeb of Science
  62. ↵
    Grodstein F, Manson JE, Stampfer MJ, Rexrode K. Postmenopausal hormone therapy and stroke: role of time since menopause and age at initiation of hormone therapy. Arch Intern Med 2008; 168: 861–6.
    OpenUrlCrossRefPubMedWeb of Science
  63. Hendrix SL, Wassertheil-Smoller S, Johnson KC, et al. Effects of conjugated equine estrogen on stroke in the Women's Health Initiative. Circulation 2006; 113; 2425–34.
    OpenUrlAbstract/FREE Full Text
  64. ↵
    Manson JE, Hsia J, Johnson KC, et al. Estrogen plus progestin and the risk of coronary heart disease. N Engl J Med 2003; 349: 523–34.
    OpenUrlCrossRefPubMedWeb of Science
  65. ↵
    Hsia J, Langer RD, Manson JE, et al. Conjugated equine estrogens and coronary heart disease: the Women's Health Initiative. Arch Intern Med 2006; 166: 357–65.
    OpenUrlCrossRefPubMedWeb of Science
  66. ↵
    Manson JE, Allison MA, Rossouw JE, et al. Estrogen therapy and coronary-artery calcification. N Engl J Med 2007; 356: 2591–602.
    OpenUrlCrossRefPubMedWeb of Science
  67. ↵
    Lobo RA. Evaluation of cardiovascular event rates with hormone therapy in healthy, early postmenopausal women: results from 2 large clinical trials. Arch Intern Med 2004; 164: 482–4.
    OpenUrlCrossRefPubMedWeb of Science
  68. ↵
    Adami S, Rossini M, Zamberlan N, Bertoldo F, Dorizzi R, Lo Cascio V. Long-term effects of transdermal and oral estrogens on serum lipids and lipoproteins in postmenopausal women. Maturitas 1993; 17: 191–6.
    OpenUrlCrossRefPubMed
  69. ↵
    Lobo RA, Bush T, Carr BR, Pickar JH. Effects of lower doses of conjugated equine estrogens and medroxyprogesterone acetate on plasma lipids and lipoproteins, coagulation factors, and carbohydrate metabolism. Fertil Steril 2001; 76: 13–24.
    OpenUrlCrossRefPubMedWeb of Science
  70. ↵
    Naessen T, Rodriguez-Macias K, Lithell H. Serum lipid profile improved by ultra-low doses of 17β-estradiol in elderly women. J Clin Endocrinol Metab 2001; 86: 2757–62.
    OpenUrlCrossRefPubMedWeb of Science
  71. ↵
    Langer RD, Friedman AJ. Effects of E2 and E2/norgestimate hormone therapy on elevated baseline lipids. J Reprod Med 2006; 51: 610–6.
    OpenUrlPubMed
Back to top

In this issue

Print
Download PDF
Article Alerts
Email Article
Citation Tools

Jump to section